Solifenacin for Overactive Bladder: Patient-Reported Outcomes from a Large Placebo-Controlled Trial

References

• . Coyne KS, Payne C, Bhattacharyya SK, . The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–463
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003;92(9):948–954
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Zhou Z, Thompson C, Versi E. The impact on health-related quality of life of stress, urge and mixed urinary incontinence. BJU Int. 2003;92(7):731–735
   PubMed Web of Science ®Google Scholar
• . Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P; International Continence Society. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn. 2006;25(3):293
   PubMed Web of Science ®Google Scholar
• . Abrams P, Cardozo L, Fall M, .; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49
   PubMed Web of Science ®Google Scholar
• . Grimby A, Milsom I, Molander U, Wiklund I, Ekelund P. The influence of urinary incontinence on the quality of life of elderly women. Age Ageing. 1993;22(2):82–89
   PubMed Web of Science ®Google Scholar
• . Hunskaar S, Vinsnes A. The quality of life in women with urinary incontinence as measured by the sickness impact profile. J Am Geriatr Soc. 1991;39(4):378–382
   PubMed Web of Science ®Google Scholar
• . O'Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics. 1998;14(5):531–539
   PubMed Web of Science ®Google Scholar
• . Wyman JF, Harkins SW, Choi SC, Taylor JR, Fantl JA. Psychosocial impact of urinary incontinence in women. Obstet Gynecol. 1987;70(3 pt 1):378–381
   PubMed Web of Science ®Google Scholar
• . Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract. 2006;60(6):752–758
   PubMed Web of Science ®Google Scholar
• . Garely AD, Kaufman JM, Sand PK, Smith N, Andoh M. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Clin Ther. 2006;28(11):1935–1946
   PubMed Web of Science ®Google Scholar
• . Donovan J, Bosch R, Gotoh M, . Symptom and Quality of Life Assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. Paris, France: Health Publication Ltd; 2005:519–584
   Google Scholar
• . Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005;48(1):5–26
   PubMed Web of Science ®Google Scholar
• . Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology. 2006;68( 2 suppl):38–48
   PubMed Web of Science ®Google Scholar
• . Chapple CR, Artibani W, Cardozo LD, . The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005;95(3):335–340
   PubMed Web of Science ®Google Scholar
• . Freeman RM. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(2):93–95
   PubMed Web of Science ®Google Scholar
• . Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2009;73(1):14–18
   PubMed Web of Science ®Google Scholar
• . Nixon A, Colman S, Sabounjian L, . A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;174(2):604–607
   PubMed Web of Science ®Google Scholar
• . Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU International. 2005;95(4):591–596
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–1086
   PubMed Web of Science ®Google Scholar
• . Coyne K, Revicki D, Hunt T, . Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563–574
   PubMed Web of Science ®Google Scholar
• . Cardozo L, Lisec M, Millard R, . Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172(5 pt 1):1919–1924
   PubMed Web of Science ®Google Scholar
• . Chapple CR, Rechberger T, Al-Shukri S, . Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93(3):303–310
   PubMed Web of Science ®Google Scholar
• . Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int. 2006;97(3):540–546
   PubMed Web of Science ®Google Scholar
• . Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology. 2006;67(2):275–280
   PubMed Web of Science ®Google Scholar
• . Staskin D, Sand P, Zinner N, Dmochowski R; Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007;178(3 pt 1):978–983
   PubMed Web of Science ®Google Scholar
• . Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71(3):449–454
   PubMed Web of Science ®Google Scholar
• . Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 pt 1):2311–2315
   PubMed Web of Science ®Google Scholar
• . Rovner ES, Kreder K, Sussman DO, . Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008;180(3):1034–1041
   PubMed Web of Science ®Google Scholar
• . Cardozo L, Hessdorfer E, Milani R, .; SUNRISE Study Group. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int. 2008;102(9):1120–1127
   PubMed Web of Science ®Google Scholar
• . Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract. 2006;60(6):745–751
   PubMed Web of Science ®Google Scholar
• . Dwyer P, Kelleher C, Young J, . Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn. 2008;27(6):540–547
   PubMed Web of Science ®Google Scholar
• . van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol. 2006;50(3):440–452
   PubMed Web of Science ®Google Scholar
• . Kelleher CJ, Kreder KJ, Pleil AM, Burgess SM, Reese PR. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care. 2002;8( 19 suppl):S616–S630
   PubMedGoogle Scholar
• . Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47(3):376–384
   PubMed Web of Science ®Google Scholar